Prestige Consumer Healthcare closed its biggest-ever acquisition on June 15, paying $1.045 billion for the Breathe Right brand and several other over-the-counter labels from Foundation Consumer Healthcare. The deal makes Breathe Right Prestige’s largest single brand and broadens the company’s presence in sleep, allergy relief and wellness categories, while also increasing the importance of integration and balance-sheet repair for investors.
Key takeaways
- Deal size and scope: Prestige completed a $1.045 billion acquisition centered on Breathe Right, adding major OTC brands including Dimetapp and Anbesol.
- Catalyst: Closing of the transaction closed on June 15, expanding Prestige’s consumer health portfolio with a new category anchor.
- Implication for investors: The acquisition boosts near-term leverage and elevates execution risk around integration and cash flow generation.
- Strategic angle: Management sees opportunities to broaden usage of Breathe Right while leveraging how other Prestige brands expanded over time.
- Bigger picture: The company is also positioning parts of its portfolio to resonate with GLP-1 medication users seeking relief from common side effects.
The Breathe Right acquisition reshapes Prestige’s OTC portfolio
Prestige’s purchase of Breathe Right and other OTC brands represents its largest transaction to date. According to the company’s deal disclosures, the acquired business adds roughly $200 million in annual revenue and about $95 million in EBITDA. Breathe Right, the nasal strip known for decades among athletes and consumers managing nighttime congestion, becomes the anchor brand within Prestige’s portfolio.
The acquisition also brings in Dimetapp, a long-standing children’s cough and cold brand, and Anbesol, which provides oral pain relief. Together, the brands expand Prestige’s reach across consumer health needs that overlap with wellness and symptom-focused care, while giving the company additional platforms for marketing and product expansion.
Management’s plan: extend category reach beyond the original use
Prestige’s strategy is centered on building brands that become strongly associated with their categories—often referred to as “category synonymous” brands. The company has historically generated about 64% of revenue from brands that hold the No. 1 position in their respective categories, according to the article.
In explaining the acquisition’s longer-term potential, CEO Ron Lombardi pointed to Prestige’s experience with Dramamine. The company acquired Dramamine when it was perceived primarily as a motion sickness product and later expanded it into a broader remedy for everyday nausea and vertigo. That expansion approach is expected to inform how Prestige develops Breathe Right by investing in consumer awareness and widening its use cases across related areas such as sleep wellness, athletic performance and allergy relief.
A quieter link to the GLP-1 side-effect economy
Another element of Prestige’s positioning is its growing attention to the ongoing GLP-1 weight-loss conversation. The report notes that as millions of Americans begin using GLP-1 therapies such as Ozempic and Wegovy, they commonly encounter side effects including nausea and digestive discomfort.
Prestige has been marketing brands such as Dramamine and Fleet toward GLP-1 users looking for symptom relief. The company’s argument is that these are existing assets—built for the symptom stack already—and that expanding their relevance to a new consumer cohort may be less costly than launching new products from scratch.
International expansion adds another leg to growth
The Breathe Right deal is not the only step Prestige is taking. The company also announced an agreement to acquire LaCorium Health, a therapeutic skincare brand in Australia. Prestige already operates in Australia through brands including Hydralyte and Fess, so the move is aimed at deepening an existing footprint rather than establishing a new operating base.
Beyond the specific transaction, the report emphasizes that international OTC healthcare remains fragmented and trust-driven—conditions that can favor brand owners with proven consumer recognition and scalable distribution.
The main risk: leverage and integration execution
While the acquisition expands Prestige’s product lineup, it also increases financial pressure. At closing, the deal pushed Prestige’s net leverage to roughly 4.0x EBITDA, according to the report. Management projected leverage returning to below 3.0x by fiscal 2028, but that outlook depends on execution.
The report highlights several execution uncertainties investors will watch: integration progress, consumer demand durability, and whether newly acquired brands respond to incremental investment as management expects. If free cash flow underperforms or integration costs rise, leverage reduction could take longer than planned.
For now, Prestige’s core thesis remains continuity: category-leading OTC brands, a repeatable acquisition model, and a fresh runway created by Breathe Right’s scale. The investment case will likely hinge on whether the company can convert that brand strength into growth while keeping debt on a path downward.
What to watch next: investors may focus on integration updates for Breathe Right and the broader acquired portfolio, evidence that marketing investments translate into sustained category momentum, and progress toward leverage reduction targets. Upcoming earnings results and management commentary—especially around cash flow and any integration-related adjustments—will be key to assessing whether the company stays on track.
